Boston Scientific Corp. (NYSE:BSX) had its price target upped by Barclays Capital from $9.00 to $12.00 in a research note issued to investors on Friday, Stock Ratings Network reports. The firm currently has an overweight rating on the stock.
A number of other firms have also recently commented on BSX. Analysts at Stifel Nicolaus raised their price target on shares of Boston Scientific Corp. from $11.00 to $13.00 in a research note to investors on Friday. They now have a buy rating on the stock. Separately, analysts at RBC Capital raised their price target on shares of Boston Scientific Corp. from $11.00 to $12.00 in a research note to investors on Friday. They now have an outperform rating on the stock. Finally, analysts at Citigroup Inc. downgraded shares of Boston Scientific Corp. from a buy rating to a neutral rating in a research note to investors on Monday, July 8th. They now have a $9.30 price target on the stock, up previously from $8.20.
Sixteen investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of Hold and a consensus price target of $9.44.
Boston Scientific Corp. (NYSE: BSX) remained flat at $10.97 during trading on Friday. Boston Scientific Corp. has a 1-year low of $5.04 and a 1-year high of $11.11. The stock’s 50-day moving average is currently $9.54. The company’s market cap is $14.693 billion.
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.